Skip to Main Content

Author Details

Mark J Routbort
University of Texas MD Anderson Cancer Center
1989
161
45
PMIDPaper TitleJournal TitlePublished Year
37981812<i>STAT5B</i> mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia.Haematologica2024
37747438Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.Cancer Cytopathol2024
36244574Recommendations for the Use of in Silico Approaches for Next-Generation Sequencing Bioinformatic Pipeline Validation: A Joint Report of the Association for Molecular Pathology, Association for Pathology Informatics, and College of American Pathologists.J Mol Diagn2023
37547448PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens.Ther Adv Med Oncol2023
37322121The NCI-MATCH trial: lessons for precision oncology.Nat Med2023
37154083DDX41 mutations in patients with non-myeloid hematologic neoplasms.Am J Hematol2023
36755027Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer.Nat Commun2023
34775472Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.Mod Pathol2022
35353553Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.J Clin Oncol2022
35504958Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.Mod Pathol2022
35467000Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma.Am J Clin Pathol2022
35430388Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia.Leuk Res2022
35820397Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.Cancer Cell2022
35690645Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.Mod Pathol2022
35390143TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.Blood2022
36671709Concurrent Mutations in <i>SF3B1</i> and <i>PHF6</i> in Myeloid Neoplasms.Biology (Basel)2022
36230473Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods.Cancers (Basel)2022
35977347Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma.JCO Precis Oncol2022
34903824Correction to: Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.Mod Pathol2022
34992253Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.Bone Marrow Transplant2022
34989420Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis.Am J Hematol2022
32667737Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells.Cytometry B Clin Cytom2021
33493304Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing.Arch Pathol Lab Med2021
33677472Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.Blood Cancer J2021
33585199Next-Generation Sequencing of <i>DDX41</i> in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations.Front Oncol2021
34161603Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.Cancer2021
33109741Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting.Clin Cancer Res2021
33450747An Overview of Characteristics of Clinical Next-Generation Sequencing-Based Testing for Hematologic Malignancies.Arch Pathol Lab Med2021
33119213Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers.Cancer Cytopathol2021
32856987Germline DNMT3A mutation in familial acute myeloid leukaemia.Epigenetics2021
31400013Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.Am J Hematol2020
31986076Proficiency Testing of Standardized Samples Shows High Interlaboratory Agreement for Clinical Next Generation Sequencing-Based Hematologic Malignancy Assays With Survey Material-Specific Differences in Variant Frequencies.Arch Pathol Lab Med2020
31922567The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design.J Natl Cancer Inst2020
31804006RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.Cancer Med2020
32005111Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.BMC Cancer2020
32848129Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.Blood Cancer J2020
33022638A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications.J Natl Compr Canc Netw2020
32183953Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.Cancer Cell2020
32112433Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.Am J Hematol2020
32238878Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.Mod Pathol2020
31211490Low-Grade Myelodysplastic Syndromes with Preserved CD34+ B-Cell Precursors (CD34+ Hematogones).Cytometry B Clin Cytom2020
30508305Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.Cancer2019
35100667Validation of <i>HER2</i> Amplification as a Predictive Biomarker for Anti-Epidermal Growth Factor Receptor Antibody Therapy in Metastatic Colorectal Cancer.JCO Precis Oncol2019
31648317ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants.Blood Adv2019
32914014Germline Genetic Predisposition to Myeloid Neoplasia From <i>GATA2</i> Gene Mutations: Lessons Learned From Two Cases.JCO Precis Oncol2019
32923865Targeting <i>ERBB2</i> (<i>HER2</i>) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications.JCO Precis Oncol2019
30171025Persistent <i>IDH1/2</i> mutations in remission can predict relapse in patients with acute myeloid leukemia.Haematologica2019
31588020Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.Cancer Cell2019
31243771Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.Br J Haematol2019
31497255Correction: A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory.Oncotarget2019
  • 1 - 50 of 161

Recommended Authors

Sebastian Uhrig
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Career Start Year 2016
Number of shared co-authors 0
Zachary L Skidmore
Washington University in St. Louis School of Medicine
Career Start Year 2015
Number of shared co-authors 3
Aparna Pallavajjala
Johns Hopkins University School of Medicine
Career Start Year 2014
Number of shared co-authors 0
Jason D Peterson
Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center
Career Start Year 2014
Number of shared co-authors 1
Mara Rosenberg
Broad Institute of MIT and Harvard
Career Start Year 2013
Number of shared co-authors 13
Hiroko Tanaka
Tokyo Medical and Dental University
Career Start Year 2012
Number of shared co-authors 5
Markus Ball
Institute of Pathology, Heidelberg University Hospital
Career Start Year 2010
Number of shared co-authors 0
Christopher A Miller
Washington University School of Medicine
Career Start Year 2009
Number of shared co-authors 9
Julien Masliah-Planchon
Curie Institute Hospital Group
Career Start Year 2008
Number of shared co-authors 2
Malak Abedalthagafi
Emory School of Medicine
Career Start Year 2008
Number of shared co-authors 1
Jennifer Dunlap
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 3
Francine B de Abreu
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 1
Kilannin Krysiak
Washington University School of Medicine
Career Start Year 2007
Number of shared co-authors 6
Linghua Wang
The University of Texas M. D. Anderson
Career Start Year 2006
Number of shared co-authors 29
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 9
Jamie K Teer
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 2005
Number of shared co-authors 3
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Career Start Year 2004
Number of shared co-authors 2
Michael D McLellan
McDonnell Genome Institute, Washington University in St. Louis
Career Start Year 2003
Number of shared co-authors 12
Sherri Z Millis
Foundation Medicine Inc
Career Start Year 2003
Number of shared co-authors 2
Peter J Campbell
Wellcome Sanger Institute
Career Start Year 2003
Number of shared co-authors 13
Trevor J Pugh
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 6
Fei Yang
Oregon Health & Science University
Career Start Year 2002
Number of shared co-authors 3
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2001
Number of shared co-authors 1
Guang Fan
Oregon Health and Science University
Career Start Year 2000
Number of shared co-authors 2
Marilyn M Li
Children's Hospital of Philadelphia
Career Start Year 2000
Number of shared co-authors 8
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 23
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 6
Seishi Ogawa
Kyoto University
Career Start Year 1993
Number of shared co-authors 9
Christopher D Gocke
Johns Hopkins University School of Medicine
Career Start Year 1992
Number of shared co-authors 3
Marc Ladanyi
Memorial Sloan Kettering Cancer Center
Career Start Year 1984
Number of shared co-authors 18

Collaborators

Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Co-authored papers 45
Guillermo Garcia-Manero
MD Anderson Cancer Center
Co-authored papers 27
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 27
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers 23
Courtney D DiNardo
UT MD Anderson Cancer Center
Co-authored papers 18
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Co-authored papers 16
Kenna R Mills Shaw
The University of Texas MD Anderson Cancer Center
Co-authored papers 16
Scott Kopetz
University of Texas MD Anderson Cancer Center
Co-authored papers 15
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 13
Alexander J Lazar
The University of Texas MD Anderson Cancer Center
Co-authored papers 13
Ken Chen
University of Texas MD Anderson Cancer Center
Co-authored papers 11
Kenneth Aldape
National Cancer Institute
Co-authored papers 10
Michael A Davies
The University of Texas MD Anderson Cancer Center
Co-authored papers 10
Pei Lin
Co-authored papers 7
Jorge Cortes
Georgia Cancer Center
Co-authored papers 6
Rakesh Nagarajan
Current or past members of the College of American Pathologists
Co-authored papers 5
Elmer V Bernstam
The University of Texas Health Science Center at Houston
Co-authored papers 5
Gautam Borthakur
MD Anderson Cancer Center
Co-authored papers 5
Anthony J Iafrate
Massachusetts General Hospital
Co-authored papers 4
Yuan Qi
Co-authored papers 4
Jason D Merker
UNC School of Medicine, The University of North Carolina at Chapel Hill
Co-authored papers 4
Phillip A Futreal
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Michelle D Williams
The University of Texas M. D. Anderson Cancer Center
Co-authored papers 4
Naoto T Ueno
Cancer Research Center of Hawaii: University of Hawai'i Cancer Center.
Co-authored papers 3
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Joel T Moncur
Walter Reed National Military Medical Center
Co-authored papers 3
Somak Roy
University of Cincinnati College of Medicine
Co-authored papers 3
Jennifer A Wargo
Co-authored papers 3
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Co-authored papers 3
Louise C Strong
University of Texas MD Anderson Cancer Center
Co-authored papers 3
Release 1.2